AI Article Synopsis
- There is growing concern about cancer misinformation on Amazon, particularly regarding books that claim to offer false cancer cures.
- A study examined the top 1000 books listed under "cancer cure" on Amazon, revealing that almost 50% contained misleading information about cancer treatment.
- The misleading books reveal themes like promoting unsupported treatment claims, oversimplifying cancer, and discrediting established medical treatments, highlighting a need for consumer awareness in health-related purchases.
Article Abstract
Background: While the evidence base on web-based cancer misinformation continues to develop, relatively little is known about the extent of such information on the world's largest e-commerce website, Amazon. Multiple media reports indicate that Amazon may host on its platform questionable cancer-related products for sale, such as books on purported cancer cures. This context suggests an urgent need to evaluate Amazon.com for cancer misinformation.
Objective: This study sought to (1) examine to what extent are misleading cancer cure books for sale on Amazon.com and (2) determine how cancer cure books on Amazon.com provide misleading cancer information.
Methods: We searched "cancer cure" on Amazon.com and retrieved the top 1000 English-language book search results. We reviewed the books' descriptions and titles to determine whether the books provided misleading cancer cure or treatment information. We considered a book to be misleading if it suggested scientifically unsupported cancer treatment approaches to cure or meaningfully treat cancer. Among books coded as misleading, we conducted an inductive latent thematic analysis to determine the informational value the books sought to offer.
Results: Nearly half (494/1000, 49.4%) of the sampled "cancer cure" books for sale on Amazon.com appeared to contain misleading cancer treatment and cure information. Overall, 17 (51.5%) out of 33 Amazon.com results pages had 50% or more of the books coded as misleading. The first search result page had the highest percentage of misleading books (23/33, 69.7%). Misleading books (n=494) contained eight themes: (1) claims of efficacious cancer cure strategies (n=451, 91.3%), (2) oversimplifying cancer and cancer treatment (n=194, 39.3%), (3) falsely justifying ineffective treatments as science based (n=189, 38.3%), (4) discrediting conventional cancer treatments (n=169, 34.2%), (5) finding the true cause of cancer (n=133, 26.9%), (6) homogenizing cancer (n=132, 26.7%), (7) discovery of new cancer treatments (n=119, 24.1%), and (8) cancer cure suppression (n=82, 16.6%).
Conclusions: The results demonstrate that misleading cancer cure books are for sale, visible, and prevalent on Amazon.com, with prominence in initial search hits. These misleading books for sale on Amazon can be conceived of as forming part of a wider, cross-platform, web-based information environment in which misleading cancer cures are often given prominence. Our results suggest that greater enforcement is needed from Amazon and that cancer-focused organizations should engage in preemptive misinformation debunking.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496910 | PMC |
| http://dx.doi.org/10.2196/56354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing ChatGPT-3.5 and ChatGPT-4's alignments with the German evidence-based S3 guideline for adult soft tissue sarcoma.
iScience
December 2024
Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Clinical reliability assessment of large language models is necessary due to their increasing use in healthcare. This study assessed the performance of ChatGPT-3.5 and ChatGPT-4 in answering questions deducted from the German evidence-based S3 guideline for adult soft tissue sarcoma (STS).
View Article and Find Full Text PDFConsensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity.
Environ Mol Mutagen
January 2025
Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Article Synopsis
- Gene expression biomarkers can help identify both genotoxic and non-genotoxic carcinogens, which could reduce the need for animal testing.
- In August 2022, a workshop reviewed current methods for using transcriptomic profiling to detect genotoxic chemicals, examining 1341 papers to find reliable biomarkers.
- The analysis identified two promising in vivo biomarkers and three in vitro biomarkers that show over 92% predictive accuracy and can be adapted for various testing conditions, with support from workshop participants for their regulatory adoption.
Online health information seeking behavior among breast cancer patients and survivors: a scoping review.
BMC Womens Health
January 2025
School of Nursing, Fudan University, 305 Fenglin Road, Shanghai, 200032, China.
Purpose: This scoping review aims to summarize online health information seeking (OHIS) behavior among breast cancer patients and survivors, identify research gaps, and offer insights for future studies.
Methods: Following Arksey and O'Malley's framework, we conducted a review across PubMed, Web of Science, CINAHL, MEDLINE, Cochrane, Embase, CNKI, Wanfang Data, and SinoMed, covering literature from 1 January 2014 to 13 August 2023. A total of 1,368 articles were identified, with 33 meeting the inclusion criteria.
Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy.
Clin Cancer Res
December 2024
Institute of Cancer Research, Sutton, London, United Kingdom.
Purpose: we tested whether ctDNA changes may be used to assess early response and clinical outcome in metastatic colorectal cancer (mCRC) patients undergoing front-line systemic anti-cancer therapy (SACT).
Experimental Design: 862 plasma samples were collected 4-weekly from baseline (BL) until disease progression in mCRC patients receiving front line SACT. ctDNA normalization was defined as ≥99% clearance after 1 month of therapy (Mo1) in the 3 variants with the highest allele frequency in BL ctDNA.
[The role of clonal hematopoiesis in the molecular diagnostics of solid tumors].
Magy Onkol
December 2024
Molekuláris Genetikai Laboratórium, Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary.
This review presents the latest molecular genetic diagnostic and clinical aspects related to clonal hematopoiesis of indeterminate potential (CHIP). CHIP belongs to the continuously expanding group of pre-cancerous conditions, increasingly recognized in routine patient care due to the development of molecular diagnostic tools and the increase in life expectancy. The incidence of CHIP mutations increases with age (1-2% in individuals aged 50 years, 15-45% in those aged 80 years).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!